ACE and neoplasm: At a higher cut-off level (73 ng/mL), ctDNA discriminated HCC patients from HCV carriers and controls (sensitivity of 69.2% and specificity of 93.3%), and its levels were associated with tumor differentiation and size but not with gender, TNM stage or levels of other proteins (tAFP and DCP) [125].